| Autor: |
Gavriilaki, E. Koravou, E.-E. Chatziconstantinou, T. Kalpadaki, C. Printza, N. Ximeri, M. Christoforidou, A. Karavalakis, G. Kaliou, M. Kalaitzidou, V. Tassi, I. Tzellou, M. Touloumenidou, T. Papalexandri, A. Papathanasiou, M. Syrigou, A. Kioumi, A. Liga, M. Kaiafa, G. Spyridonidis, A. Kapsali, E. Kollios, K. Mandala, E. Vlachaki, E. Tsirigotis, P. Papadaki, E. Lalayanni, C. Sakellari, I. Anagnostopoulos, A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
ADAMTS13 (A Disintegrin and Metalloprotease with ThromboSpondin type 1 motifs) activity is a key tool in differential diagnosis of thrombotic microangiopathies (TMAs). Due to the lack of availability of ADAMTS13 testing, PLASMIC/PLASIC scores have been suggested to predict ADAMTS13 deficiency. The importance of differentiating TTP from other complement-mediated TMAs is highlighted by the need to urgently start plasma exchange and utility of treatments such as caplacizumab or eculuzimab. Therefore, we aimed to evaluate ADAMTS13 activity, PLASMIC/PLASIC scores, and complement testing in guiding management of a real-world TMA cohort. We enrolled consecutive TMA patients with samples referred to our Center (01/2018–2020). If ADAMTS13 > 10%, soluble C5b-9 was measured. Among 80 TMA patients, ADAMTS13 activity was ≤10% in 50 patients, while 28 had a relapsing disease. PLASMIC/PLASIC were excellent predictors of ADAMTS13 deficiency, especially in patients without secondary causes. Soluble C5b-9 levels were elevated (median 525 ng/ml, range 313–913 ng/ml) in 7 patients without secondary causes and ADAMTS13 > 10% (hemolytic uremic syndrome/HUS). Two were shiga-toxin associated; while 5 atypical HUS. Only 1/5 patients received eculizumab and achieved TMA resolution implemented by guidance based on soluble C5b-9 levels. In transplant-associated TMA, 8/16 patients not responding to first-line treatment received eculizumab due to elevated C5b-9 levels (median 353 ng/ml, range 281–1252 ng/ml) and achieved TMA resolution. In conclusion, our real-world data confirm that ADAMTS13, complement testing, and PLASMIC/PLASIC are valuable tools in diagnosis and management of TMAs, but also highlight the unmet need of using available markers and treatments in clinical practice. © 2021 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
